Research Liquids
-
T3 (Liothyronine) 100mcg Per ML 60ml Bottle w/ Dropper
Regular Price: $45.99
Special Price: $39.99
Buy T3 (Liothyronine) - T3 (Liothyronine) 100mcg x 60ml Bottle w/ Dropper T3 from Great White Peptides - GWP offers the highest quality research grade T3 on the market today with fast shipping of T3 (Liothyronine) 100mcg. T3 (Liothyronine) 100mcg x 60ml vial sodium (2S)-2-amino-3- [4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl] propanoate Formula C15H11I3NNaO4 Mol. mass 672.96 g/mol Liothyronine sodium is the L-isomer of triiodothyronine (T3), a form of thyroid hormone used to treat hypothyroidism and myxedema coma. It is marketed under the brand name Cytomel (or Tertroxin in Australia). Liothyronine is the most potent form of thyroid hormone. As such, it acts on the body to increase the basal metabolic rate, affect protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline) by permissiveness. The thyroid hormones are essential to proper development and differentiation of all cells of the human body. These hormones also regulate protein, fat, and carbohydrate metabolism, affecting how human cells use energetic compounds. In comparison to levothyroxine (T4), liothyronine has a faster onset of action as well as a shorter biological half-life, which may be due to less plasma protein binding to thyroxine-binding globulin and transthyretin. Buy T3 100mcg from Great White Peptides
Learn More | Add to Wishlist | Add to Compare -
MK-2866 25MG PER ML 60 ML BOTTLE W MARKED DROPPER
Regular Price: $139.99
Special Price: $110.00
841205-47-8 MF C19H14F3N3O3 Type Antineoplastic Agents, Immune Function Agents Purity 99% Purity 99% CAS 841205-47-8 Molecular Formula C19H14F3N3O3 Molecular Weight 441.11 Ostarine ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) (also known as MK-2866) is an investigational selective androgen receptor modulator (SARM) from GTx Inx, for treatment of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company.[1] According to a recent paper authored by GTx, "Readers are cautioned to note that the name Ostarine is often mistakenly linked to the chemical structure of [S-4], which is also known as andarine. The chemical structure of Ostarine has not been publicly disclosed."[2] While GTx has not formally disclosed the structure of Ostarine, the chemical composition of Ostarine is revealed in patent databases such the WIPO[3] and discussed by Zhang et al., 2009 in the primary literature.[4] Various SARM chemotypes exist (aryl propionamides, quinolines, quinolinones, bicyclic hydantoins), though aryl propionamides such as Ostarine, Andarine/S-4, and S-23 represent some of the most advanced putative therapeutics under investigation.[5] In terms of atom connectivity, Ostarine differs from Andarine by cyano substitutions on the phenyl rings as it replaces both the nitro and acetamido moieties. In December 2006, GTx completed a 3 month Phase II double-blind, randomized, placebo-controlled clinical trial in 120 subjects (60 elderly men and 60 postmenopausal women). Ostarine treatment resulted in a dose-dependent increase in lean body mass (LBM), with those taking the highest dose of 3 mg per day showing an average LBM increase of 1.4 kg (3.1 lbs) compared to those who received placebo. The Ostarine treatment also resulted in improvement in muscle function (performance) in a 12 stair climb test measuring speed and power. Ostarine had a favorable safety profile, with no serious adverse events reported. Ostarine also exhibited tissue selectivity with beneficial effects on lean body mass and performance and with no apparent change in measurements of serum PSA, sebum production or serum LH.[6] In October 2008, GTx announced topline results of the Phase II trial evaluating Ostarine in patients with cancer cachexia. The clinical trial enrolled 159 cancer patients (average age of 66 years) with non-small cell lung cancer, colorectal cancer, non-Hodgkin lymphoma, chronic lymphocytic leukemia or breast cancer at 35 sites in the U.S. and Argentina. Participants were randomized to receive placebo, 1 mg or 3 mg oral capsule of Ostarine once daily for 16 weeks. Average reported weight loss prior to entry among all subjects was 8.8%. Subjects were allowed to have standard chemotherapy during the trial. The study met its primary endpoint of absolute change in total lean body mass (muscle) compared to placebo and the secondary endpoint of muscle function (performance). The incidence of serious adverse events, deaths and tumor progression were similar among placebo and the treatment arms. The most common side effects reported among all subjects in the trial were fatigue, anemia, nausea and diarrhea.[6] GTx and Merck had clinical development plans to evaluate Ostarine for the treatment of muscle loss in patients with COPD and for the treatment of chronic sarcopenia. They had a goal of initiating an Ostarine Phase II COPD clinical trial in the first quarter of 2010 and an Ostarine Phase IIb chronic sarcopenia clinical trial in 2010.[7]
Learn More | Add to Wishlist | Add to Compare -
FOREMESTANE (50MG PER 1ML 60ML BOTTLE WITH MARKED MEASURING DEVICE)
$35.0050MG PER 1ML 60ML BOTTLE OF FOREMESTANE Formestane (Lentaron) is a type I, steroidal aromatase inhibitor. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection. Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor. Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified
Learn More | Add to Wishlist | Add to Compare -
RIMONABANT (25MG PER 1ML 60ML BOTTLE W MARKED MEASURING DEVICE)
$40.00RIMONABANT 25MG PER 1ML 60 mL BOTTLE FOR RESEARCH PURPOSES ONLY
Learn More | Add to Wishlist | Add to Compare -
RALOXIFENE (50MG PER 1ML 60ML BOTTLE W MARKED MEASURING DEVICE)
Regular Price: $55.00
Special Price: $45.00
RALOXIFENE 5OMG PER 1ML 60 ML Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition. Raloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
Learn More | Add to Wishlist | Add to Compare -
DUTASTERIDE (.5MG PER 1ML 60ML BOTTLE W MARKED MEASURING DEVICE)
$55.00DUTASTERIDE .5MG PER 1ML 60ML FOR RESEARCH PURPOSES ONLY Hair loss occurs due to an excess of androgens. The primary male androgen(test) is changed into a secondary more powerful androgen , dihydrotestosterone. It is this potent androgen that is responsible for hair loss. Dutast works by blocking the 5ar isoenzymes responsible for the aforementioned conversion of test to dihydrotestosterone. Thus eliminating the normal effect of hair loss due to elevated dihydrotestosterone levels. It has also been show that in research subjects where exogenous androgens are being administered (ie: test) that dutast will not in any way inhibit the ability of the research test subjects to build lean body mass – a commonly held misconception. Dutasteride is used alone or with another medication (tamsulosin [Flomax]) to treat benign prostatic hyperplasia (BPH; enlargement of the prostate gland). Dutasteride is used to treat symptoms of BPH and may reduce the chance of developing acute urinary retention (sudden inability to urinate). Dutasteride may also decrease the chance that prostate surgery will be needed. Dutasteride is in a class of medications called 5-alpha reductase inhibitors. It works by blocking the production of a natural substance that enlarges the prostate. Refs: *Olsen EA, Hordinsky M, Whiting D, et al. (Dec 2006). "The importance of dual 5alpha-reductase inhibition in the treatment of MPB: results of a randomized placebo-controlled study of dutasteride versus finasteride". J Am Acad Dermatol. 55 (6): 1014–23. doi:10.1016/j.jaad.2006.05.007. PMID 1711021 *JAMA. 2012 Mar 7;307(9):931-9.Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, Ngyuen AH, Davda MN, Jara H, Aakil A, Anderson S, Knapp PE, Hanka S, Mohammed N, Daou P, Miciek R, Ulloor J, Zhang A, Brooks B, Orwoll K, Hede-Brierley L, Eder R, Elmi A, Bhasin G, Collins L, Singh R, Basaria S. Source: Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine and Boston Medical Center, 670 Albany St, Boston, MA 02118, USA. bhasin@bu.edu
Learn More | Add to Wishlist | Add to Compare -
ALT-711 (15MG PER 1ML 60ML BOTTLE W MARKED MEASURING DEVICE)
$79.99ALT-711 15MG PER 1ML 60ML FOR RESEARCH PURPOSE ONLY
Learn More | Add to Wishlist | Add to Compare -
T4 (Levothyroxine) 100MCGS PER 1ML 60ML BOTTLE
$34.99T4 100MCGS 60ML
Learn More | Add to Wishlist | Add to Compare